ArticleFrontiers in neurology2025
A nomogram for predicting post-stroke cognitive impairment no dementia in patients with first-ever mild ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular biomarkers of cognitive impairment and neuropsychiatric symptoms after stroke in late-life-enriched cohorts: a scoping review.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify significant predictors and construct a validated nomogram for predicting post-stroke cognitive impairment no dementia (PSCIND) risk among first-ever mild ischemic stroke (MIS) patients. Methods: This retrospective cohort study analyzed 242 first-ever MIS patients categorized into normal cognitive ( Results: Eight independent predictors were identified: age (OR = 1.060, 95% CI: 1.016-1.106), education level (OR = 0.917, 95% CI: 0.845-0.995), type 2 diabetes mellitus (OR = 9.407, 95% CI: 3.761-23.528), superoxide dismutase (OR = 0.951, 95% CI: 0.931-0.972), uric acid (OR = 1.006, 95% CI: 1.002-1.010), homocysteine (OR = 1.058, 95% CI: 1.027-1.091), strategic infarcts (OR = 4.566, 95% CI: 2.148-9.707), and severe CSVD burden (OR = 3.818, 95% CI: 1.842-7.911). The nomogram exhibited excellent discrimination (AUC = 0.886) accompanied by satisfactory calibration (Hosmer-Lemeshow Conclusion: This validated nomogram incorporating clinical, biochemical, and neuroimaging biomarkers provides a robust tool for individualized PSCIND risk assessment in first-ever MIS patients, with potential to guide targeted interventions and cognitive monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.